Insmed added longer-term support for its pulmonary arterial hypertension therapy TPIP (treprostinil palmitil inhalation powder), reporting data from an open-label extension of a Phase IIb trial. Patients in the treated arm maintained benefits over 24 months, while the prior placebo group switching to TPIP showed similar improvements after 12 months. Insmed emphasized that outcome measures were assessed 24 hours after the last TPIP administration, underscoring the company’s positioning of once-daily dosing effectiveness. The company contrasted TPIP’s schedule with more frequent administration regimens used for other inhaled prostacyclin therapies. Together with the EMA-focused Elevidys Phase III restart, the developments highlight how late-stage evidence and durability endpoints continue to drive confidence in therapies where regulatory scrutiny and clinical differentiation are decisive.